Akebia Therapeutics AKBA 深 沪
等待开盘 08-17 09:30:00 美东时间
0.8728
+0.003
+0.37%
华盛通- 最 高0.8882
- 今 开0.87
- 成交量 208.75万股
- 最 低 0.8581
- 昨 收 0.8696
- 总市值 2.42亿
- 52周最高 3.22
- 市盈率 静 --
- 换手率 0.75%
- 52周最低 0.8227
- 委 比 99.60%
- 总股本 2.77亿
- 历史最高 31.00
- 量 比 0.33
- 振 幅 3.46%
- 历史最低 0.241
- 每 手 1
- 风险率 0.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Leerink Partners Downgrades Akebia Therapeutics to Market Perform, Announces $1 Price Target
Leerink Partners analyst Roanna Ruiz downgrades Akebia Therapeutics (NASDAQ:AKBA) from Outperform to Market Perform and announces $1 price target.
08-08 08:20
Western Digital, Applovin, Zillow Group And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining over 100 points on Thursday. Shares of Western Digital Corp (NASDAQ:WDC) fell sharply in pre-market trading following fourth-quarter results. Western Digital reported quarterly earnings of $3.56 per share, which beat the Street...
08-06 20:04
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics granted two new employees stock options for 61,000 shares at $1.32 per share, vesting over four years. The options were granted under Nasdaq Listing Rule 5635(c)(4) and have a 10-year term.
08-03 20:05
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics plans to release its second-quarter 2026 financial results on August 5, 2026, followed by a conference call at 4:30 p.m. EDT to discuss the results and recent business highlights. Participants can join by dialing (646) 307-1963 or toll-free (800) 715-9871 with passcode 4727037, or via webcast at ir.akebia.com. An archive of the webcast will also be available on the company’s website.
07-29 12:00
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
Monopar Therapeutics Inc. has appointed seasoned commercial leaders to support the anticipated launch of its first product, ALXN1840, for Wilson disease, pending FDA approval. Nicole Sweeny, former Chief Commercial Officer of KalVista Pharmaceuticals, has joined the Board of Directors. Sharon Funk and Daniel Olmstead have been appointed as Senior Vice Presidents for Sales and Marketing, and Market Access, Distribution, and Patient Services, respe...
07-20 12:00
Insider Shake-Up: GC, Akebia, Perion, Paychex, Arqit
Insiders have been trading these 5 stocks: (($STRL)), (($AKBA)), (($PERI)), (($...
07-04 21:01
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Akebia Therapeutics granted stock options to three new employees on June 30, 2026, allowing them to purchase a total of 125,600 shares at $1.14 per share. The options vest over four years, with 25% vesting after the first year and the remaining 75% vesting quarterly, contingent on continued employment. Each option has a 10-year term and aligns with Nasdaq Listing Rule 5635(c)(4). Akebia, a biopharmaceutical company focused on improving lives i...
07-02 20:05
美股大行评级 | 潜在涨幅392.61%！Chardan Capital维持EyePoint"买入"评级，上调目标价至65美元
今日重点评级关注：Chardan Capital：维持EyePoint"买入"评级，目标价从29美元升至65美元；康托·菲茨杰拉德：维持Hyperliquid Strategies"超配"评级，目标价从8美元升至18.4美元
07-02 18:41
Akebia Therapeutics, U.S. Renal Care Announce U.S. Renal Care Kidney Research Proposed To Halt Vafseo Outcomes In Center Experience Study After Planned Interim Analysis Based On Recommendation From Independent Data Monitoring Committee, Trial Steering Committee
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation’s largest privately held and fastest-growing kidney care provider, are pleased to announce today the decision by US...
06-30 20:09
